Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia

Andrew H. Baker, Vincenzo Sica, Lorraine M. Work, Sharon Williams-Ignarro, Filomena De Nigris, Lilach O. Lerman, Amelia Casamassimi, Alessandro Lanza, Concetta Schiano, Monica Rienzo, Louis J. Ignarro, Claudio Napoli

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Despite advances in imaging, understanding the underlying pathways, and clinical translation of animal models of disease there remains an urgent need for therapies that reduce brain damage after stroke and promote functional recovery in patients. Blocking oxidant radicals, reducing matrix metalloproteinase-induced neuronal damage, and use of stem cell therapy have been proposed and tested individually in prior studies. Here we provide a comprehensive integrative management approach to reducing damage and promoting recovery by combining biological therapies targeting these areas. In a rat model of transient cerebral ischemia (middle cerebral artery occlusion) gene delivery vectors were used to overexpress tissue inhibitor of matrix metalloproteinase 1 and 2 (TIMP1 and TIMP2) 3 days before ischemia. After occlusion, autologous bone marrow cells alone or in combination with agents to improve NO bioavailability were administered intraarterially. When infarct size, BrdU incorporation, and motor function recovery were determined in the treatment groups the largest beneficial effect was seen in rats receiving the triple combined therapy, surpassing effects of single or double therapies. Our study highlights the utility of combined drug, gene, and cell therapy in the treatment of stroke.

Original languageEnglish (US)
Pages (from-to)3597-3602
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number9
DOIs
StatePublished - Feb 27 2007

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia'. Together they form a unique fingerprint.

  • Cite this

    Baker, A. H., Sica, V., Work, L. M., Williams-Ignarro, S., De Nigris, F., Lerman, L. O., Casamassimi, A., Lanza, A., Schiano, C., Rienzo, M., Ignarro, L. J., & Napoli, C. (2007). Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3597-3602. https://doi.org/10.1073/pnas.0611112104